Roche’s PATHWAY test was used in Enhertu’s DESTINY-Breast06 clinical trial, which demonstrated a median progression-free survival of 13.2 months with the antibody-drug conjugate compared to 8. ...

(IN BRIEF) Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify ... for manual testing and Her-2/neuTest 4B5 ...

Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibody-based drugs.

pitting it against Roche's antibody therapy Ocrevus (ocrelizumab). The drugmaker reported results from the main FENopta trial last year. Fenebrutinib is currently the only reversible, non-covalent ...

Make sure your squat rack has safety features like the spotter's arms. You also want it to have the option to adjust the height of the rack for multiple users of different heights.

NEW YORK – Glasgow-based diagnostics firm Dxcover said that it has secured $6.2 million in a recent funding round aimed at further developing its early cancer detection technologies and expanding into ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...